NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, the fast-growing biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), is close to delivering a revolutionary new product poised to potentially change the lives of millions of drug and alcohol addicts around the globe. Alongside joint venture partner TheraKine, RBCC is moving forward with Phase II of development on a groundbreaking new drug delivery technology for Naltrexone, a pharmaceutical used to help treat alcohol and opioid dependence. The drug works by blocking the effects of narcotics, especially the cravings that keeps many addicts returning to opiates and alcohol again and again.
Help employers find you! Check out all the jobs and post your resume.
